Emerging molecularly targeted therapies in castration refractory prostate cancer.

PubWeight™: 0.83‹?›

🔗 View Article (PMC 3684034)

Published in Prostate Cancer on May 08, 2013

Authors

Jesal C Patel1, Benjamin L Maughan, Archana M Agarwal, Julia A Batten, Tian Y Zhang, Neeraj Agarwal

Author Affiliations

1: Division of Medical Oncology, University of UT Huntsman Cancer Institute, Salt Lake City, Utah 84112, USA.

Associated clinical trials:

Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | NCT00638690

Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT00861614

Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT01057810

Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | NCT00887198

Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy (AFFIRM) | NCT00974311

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer (Prospect) | NCT01322490

A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer (PREVAIL) | NCT01212991

Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01193257

Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer (READY) | NCT00744497

Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer | NCT01193244

Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer (VENICE) | NCT00519285

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2) | NCT01522443

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 (COMET-1) | NCT01605227

Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | NCT01145508

Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer (SYNERGY) | NCT01188187

Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | NCT00110214

A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer | NCT01234311

Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer | NCT00450463

Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy (SUN 1120) | NCT00676650

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC) | NCT01171898

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer | NCT00859781

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer (AFFINITY) | NCT01578655

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | NCT01083615

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate | NCT01685268

ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer (ARMOR1) | NCT00959959

Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | NCT01685125

A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer | NCT01288911

Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer | NCT00574769

Efficacy and Safety Study of Panobinostat in Patients With Metastatic Hormone Refractory Prostate Cancer | NCT00667862

A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients | NCT00503984

Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer | NCT01026623

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration | NCT00878436

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer (STRIVE) | NCT01664923

A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC) | NCT00571675

Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC) | NCT00313781

Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate | NCT00085228

Cediranib Maleate With or Without Dasatinib in Patients With Hormone-Resistant Prostate Cancer Resistant to Treatment With Docetaxel | NCT01260688

The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer | NCT00459186

Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer | NCT00330161

SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer | NCT01075308

AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | NCT00513071

A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer | NCT01337518

RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer | NCT00629525

Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer | NCT00520481

Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel | NCT01051570

Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002) | NCT00777959

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | NCT01270880

Saracatinib in Treating Patients With Prostate Cancer | NCT01267266

Articles cited by this

Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75

Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58

Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79

Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69

Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (2011) 11.28

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst (2004) 5.87

Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev (2003) 4.62

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell (2010) 4.16

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16

Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol (2009) 3.13

Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer (2003) 2.43

A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res (2007) 2.24

Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.76

Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res (2009) 1.71

The role of Src in prostate cancer. Ann Oncol (2007) 1.71

Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther (2008) 1.59

The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep (2008) 1.57

Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer (2010) 1.57

CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol (2008) 1.49

Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol (2011) 1.38

An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res (2009) 1.36

A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol (2010) 1.32

Strategies for cancer vaccine development. J Biomed Biotechnol (2010) 1.26

Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol (2003) 1.24

Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol (2010) 1.22

Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res (2010) 1.22

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol (2001) 1.21

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer (2009) 1.19

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol (2009) 1.19

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer (2010) 1.14

The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer. Expert Opin Investig Drugs (2010) 1.11

Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts. Mol Cancer Ther (2007) 1.11

Targeted therapeutic approaches for hormone-refractory prostate cancer. Cancer Treat Rev (2010) 1.06

Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett (2009) 1.04

Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer (2010) 1.03

Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer. Mol Cancer Ther (2011) 1.00

Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int (2007) 0.95

Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer. Urol Oncol (2009) 0.87

Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther (2007) 0.85

Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. Future Oncol (2010) 0.82

Androgen receptor signalling in prostate cancer: the functional consequences of acetylation. J Biomed Biotechnol (2010) 0.80

Emerging vaccine therapy approaches for prostate cancer. Rev Urol (2010) 0.78

Articles by these authors

Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 6.55

Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol (2012) 3.65

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol (2013) 3.19

Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol (2012) 2.84

Bladder cancer. J Natl Compr Canc Netw (2013) 2.46

NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol (2013) 2.29

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol (2014) 2.19

Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. Exp Hematol (2007) 1.98

Hematopoiesis is not clonal in healthy elderly women. Blood (2008) 1.95

Socio-demographic correlates of breast-feeding in urban slums of Chandigarh. Indian J Med Sci (2006) 1.94

Expression of cone-photoreceptor-specific antigens in a cell line derived from retinal tumors in transgenic mice. Invest Ophthalmol Vis Sci (2004) 1.92

NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw (2009) 1.86

CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res (2010) 1.78

Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. J Clin Invest (2010) 1.64

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol (2009) 1.48

Kinase-dependent differentiation of a retinal ganglion cell precursor. Invest Ophthalmol Vis Sci (2006) 1.47

Detection of JAK2 mutations in paraffin marrow biopsies by high resolution melting analysis: identification of L611S alone and in cis with V617F in polycythemia vera. Leuk Lymphoma (2012) 1.46

Hsp27 upregulation by HIF-1 signaling offers protection against retinal ischemia in rats. Invest Ophthalmol Vis Sci (2005) 1.40

Repression of Six3 by a corepressor regulates rhodopsin expression. Proc Natl Acad Sci U S A (2007) 1.38

Oxidative stress in glaucoma: a burden of evidence. J Glaucoma (2007) 1.36

Induced autoimmunity to heat shock proteins elicits glaucomatous loss of retinal ganglion cell neurons via activated T-cell-derived fas-ligand. J Neurosci (2008) 1.30

Elevated hydrostatic pressure triggers mitochondrial fission and decreases cellular ATP in differentiated RGC-5 cells. Invest Ophthalmol Vis Sci (2007) 1.30

The sigma receptor ligand (+)-pentazocine prevents apoptotic retinal ganglion cell death induced in vitro by homocysteine and glutamate. Brain Res Mol Brain Res (2004) 1.23

Light induces programmed cell death by activating multiple independent proteases in a cone photoreceptor cell line. Invest Ophthalmol Vis Sci (2007) 1.13

Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer (2013) 1.12

Retinal ganglion cell line apoptosis induced by hydrostatic pressure. Brain Res (2006) 1.12

Serum deprivation induces apoptotic cell death of transformed rat retinal ganglion cells via mitochondrial signaling pathways. Invest Ophthalmol Vis Sci (2005) 1.11

Testicular cancer. J Natl Compr Canc Netw (2012) 1.11

Analysis of sigma receptor (sigmaR1) expression in retinal ganglion cells cultured under hyperglycemic conditions and in diabetic mice. Brain Res Mol Brain Res (2002) 1.10

Interleukin-10 receptor signaling through STAT-3 regulates the apoptosis of retinal ganglion cells in response to stress. Invest Ophthalmol Vis Sci (2003) 1.10

Role of PPAR-gamma ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells. Invest Ophthalmol Vis Sci (2003) 1.09

Peroxisome proliferator-activated receptor alpha negatively regulates T-bet transcription through suppression of p38 mitogen-activated protein kinase activation. J Immunol (2003) 1.07

OPA1 expression in the normal rat retina and optic nerve. J Comp Neurol (2005) 1.06

Calpeptin provides functional neuroprotection to rat retinal ganglion cells following Ca2+ influx. Brain Res (2006) 1.06

Kidney cancer. J Natl Compr Canc Netw (2011) 1.06

Sickle cell disease resulting from uniparental disomy in a child who inherited sickle cell trait. Blood (2010) 1.04

Soluble CD44 is cytotoxic to trabecular meshwork and retinal ganglion cells in vitro. Invest Ophthalmol Vis Sci (2005) 1.02

A glaucoma-associated mutant of optineurin selectively induces death of retinal ganglion cells which is inhibited by antioxidants. Invest Ophthalmol Vis Sci (2007) 1.02

Kidney cancer, version 2.2014. J Natl Compr Canc Netw (2014) 0.98

Metabolic syndrome: a challenging health issue in highly urbanized Union Territory of north India. Diabetol Metab Syndr (2010) 0.97

Metastatic potential of tumor-initiating cells in solid tumors. Front Biosci (Landmark Ed) (2011) 0.97

Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2013) 0.97

Levels of fatigue and distress in senior prostate cancer survivors enrolled in a 12-week randomized controlled trial of Qigong. J Cancer Surviv (2013) 0.96

Multidrug-resistant MCF-7 breast cancer cells contain deficient intracellular calcium pools. Breast Cancer Res Treat (2002) 0.96

The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol (2013) 0.95

Sequencing systemic therapies for metastatic kidney cancer. Curr Treat Options Oncol (2015) 0.95

Erythropoiesis in polycythemia vera is hyper-proliferative and has accelerated maturation. Blood Cells Mol Dis (2009) 0.93

Methylation of AR locus does not always reflect X chromosome inactivation state. Blood (2012) 0.93

The role of CaMKII in BDNF-mediated neuroprotection of retinal ganglion cells (RGC-5). Brain Res (2005) 0.92

Neuroprotective effects of minocycline against in vitro and in vivo retinal ganglion cell damage. Brain Res (2005) 0.92

Heat shock protein 27 delays Ca2+-induced cell death in a caspase-dependent and -independent manner in rat retinal ganglion cells. Invest Ophthalmol Vis Sci (2005) 0.91

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clin Cancer Res (2013) 0.91

Empirically identified goals for the management of unexplained symptoms. Fam Med (2006) 0.90

A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer (2014) 0.90

Management of cancer-associated thrombotic microangiopathy: what is the right approach? Am J Hematol (2007) 0.90

Microarray reveals complement components are regulated in the serum-deprived rat retinal ganglion cell line. Mol Vis (2007) 0.89

Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat Rev (2013) 0.89

IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys (2010) 0.88

Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments. Curr Urol Rep (2013) 0.88

A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int (2014) 0.86

Testicular Cancer, Version 2.2015. J Natl Compr Canc Netw (2015) 0.86

Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma. Target Oncol (2013) 0.85

Retinal ganglion cell death and neuroprotection: Involvement of the CaMKIIalpha gene. Brain Res Mol Brain Res (2005) 0.85

Role of nonfeminizing estrogen analogues in neuroprotection of rat retinal ganglion cells against glutamate-induced cytotoxicity. Free Radic Biol Med (2005) 0.85

Recent advances in immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther (2011) 0.85

Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. Clin Genitourin Cancer (2013) 0.85

A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw (2012) 0.85

KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors. Cancer Res (2013) 0.84

Molecular-wire behavior of OLED materials: exciton dynamics in multichromophoric Alq3-oligofluorene-Pt(II)porphyrin triads. J Am Chem Soc (2006) 0.84

Prostate cancer risk prediction based on complete prostate cancer family history. Prostate (2014) 0.84

Novel molecular aberrations and pathologic findings in a tubulocystic variant of renal cell carcinoma. Indian J Pathol Microbiol (2014) 0.84

Patient and provider attitudes toward genomic testing for prostate cancer susceptibility: a mixed method study. BMC Health Serv Res (2013) 0.83

A population-based analysis of clustering identifies a strong genetic contribution to lethal prostate cancer. Front Genet (2013) 0.83

Clinical profile of epilepsy, in a tertiary care centre of North-west India. J Indian Med Assoc (2011) 0.82

Acute kernicterus in a neonate with O/B blood group incompatibility and a mutation in SLC4A1. Pediatrics (2013) 0.82

An unusual cause of psychosis. Lancet (2004) 0.82

Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer (2014) 0.82

Coronary cameral fistula treated by the Amplatzer vascular plug. Jpn J Radiol (2014) 0.82

Community physicians' strategies for patients with medically unexplained symptoms. Fam Med (2008) 0.81

Activin receptor inhibitors--dalantercept. Curr Oncol Rep (2015) 0.81

Feasibility and acceptability of a Tai Chi Chih randomized controlled trial in senior female cancer survivors. Integr Cancer Ther (2013) 0.81

Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma. J Immunother (2014) 0.81

Differing leukocyte gene expression profiles associated with fatigue in patients with prostate cancer versus chronic fatigue syndrome. Psychoneuroendocrinology (2013) 0.80

Ipilimumab in the treatment of prostate cancer. Future Oncol (2015) 0.80

Novel exon 2 α spectrin mutation and intragenic crossover: three morphological phenotypes associated with four distinct α spectrin defects. Haematologica (2013) 0.80

BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma. Laryngoscope (2014) 0.80

Blood pressure, salivary cortisol, and inflammatory cytokine outcomes in senior female cancer survivors enrolled in a tai chi chih randomized controlled trial. J Cancer Surviv (2014) 0.80

Photoreceptor cell apoptosis induced by the 2-nitroimidazole radiosensitizer, CI-1010, is mediated by p53-linked activation of caspase-3. Neurotoxicology (2005) 0.79

Nipradilol protects rat retinal ganglion cells from apoptosis induced by serum deprivation in vitro and by diabetes in vivo. Curr Eye Res (2008) 0.79

Best practices for use of the HEMOX analyzer in the clinical laboratory: quality control determination and choice of anticoagulant. Lab Hematol (2012) 0.79

Over-expression of TRPM8 is associated with poor prognosis in urothelial carcinoma of bladder. Tumour Biol (2014) 0.79

Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Target Oncol (2013) 0.79

MDM2 binding protein, a novel metastasis suppressor. Cancer Metastasis Rev (2012) 0.78

Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. Am J Med Sci (2010) 0.78

Novel α-spectrin mutation in trans with α-spectrin causing severe neonatal jaundice from hereditary spherocytosis. Neonatology (2014) 0.78

Variations in both α-spectrin (SPTA1) and β-spectrin ( SPTB ) in a neonate with prolonged jaundice in a family where nine individuals had hereditary elliptocytosis. Neonatology (2013) 0.78

Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors. Invest New Drugs (2015) 0.78

Obesity and treatment of prostate cancer: what is the right dose of Lupron Depot? Clin Cancer Res (2007) 0.77